Twi Biotechnology Inc., of Taipei, Taiwan, completed patient enrollment in its phase II trial with AC-201CR for the treatment of gout. The company expects to report top-line results from this study in the fourth quarter of 2016. The positive interim results of the proof-of-concept study were made public late last year. AC-201 is described as a first-in-class, orally available small molecule which has shown the dual abilities to inhibit URAT1 as well as the production and activity of caspase-1 and the cytokine interleukin-1 beta through the inhibition of the assembly of the NLRP3 inflammasome.